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Background:We compared viral subpopulations derived from humanized liver mouse model versus cell culture.
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Significance: HCV produced from humanized liver mice may better reflect the characteristics of virus from HCV-infected
patients.
Lipoprotein components are crucial factors for hepatitis C
virus (HCV) assembly and entry. As hepatoma cells producing
cell culture-derived HCV (HCVcc) particles are impaired in
some aspects of lipoprotein metabolism, it is of upmost interest
to biochemically and functionally characterize the in vivo pro-
duced viral particles, particularly regarding how lipoprotein
components modulate HCV entry by lipid transfer receptors
such as scavenger receptor BI (SR-BI). Sera from HCVcc-in-
fected liver humanized FRGmicewere separated by density gra-
dients. Viral subpopulations, termed HCVfrg particles, were
characterized for their physical properties, apolipoprotein asso-
ciation, and infectivity. We demonstrate that, in contrast to the
widely spread distribution of apolipoproteins across the differ-
ent HCVcc subpopulations, the most infectious HCVfrg parti-
cles are highly enriched in apoE, suggesting that such apolipo-
protein enrichment plays a role for entry of in vivo derived
infectious particles likely via usage of apolipoprotein receptors.
Consistent with this salient feature, we further reveal previously
undefined functionalities of SR-BI in promoting entry of in vivo
producedHCV. First, unlike HCVcc, SR-BI is a particularly lim-
iting factor for entry of HCVfrg subpopulations of very low den-
sity. Second, HCVfrg entry involves SR-BI lipid transfer activity
but not its capacity to bind to the viral glycoprotein E2. In con-
clusion, we demonstrate that composition and biophysical
properties of the different subpopulations of in vivo produced
HCVfrg particles modulate their levels of infectivity and recep-
tor usage, hereby featuring divergences with in vitro produced
HCVcc particles and highlighting the powerfulness of this in
vivo model for the functional study of the interplay between
HCV and liver components.
To complete its life cycle and to produce new infectious par-
ticles, HCV7 hijacks the host lipid metabolism. Indeed, it has
been demonstrated that HCV assembly is tightly connected to
the assembly pathway of very low density lipoprotein (VLDL).
In the most considered assembly model, the nascent nucleo-
capsids fuse with VLDL precursors during the VLDL matura-
tion process across the endoplasmic reticulum membranes.
Before leaving the cells, these lipoproteins acquire lipids and
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apolipoproteins such as apoB, apoE, and apoC and are then
secreted through the Golgi apparatus (1–3).
The association of HCV particles with lipoprotein compo-
nents such as lipids and apolipoproteins was initially demon-
strated for particles retrieved from the peripheral blood of
infected patients (4–6). Such HCV particles, called lipoviro-
particles (LVPs), resemble very low and low density lipopro-
teins andhave a heterogeneous distribution in densities ranging
from less than 1.06 to 1.25 g/ml (7). Cell culture-derived HCV
(HCVcc) as well as LVPs can also be immunoprecipitated
with antibodies against apoE and apoB (8–10). Moreover, a
direct interaction between apoE and viral envelope glyco-
proteins has recently been demonstrated (11–13), further
indicating a close relationship between viral particles and
lipoprotein components.
Lipoproteins and their receptors as well as their associated
lipid transfer activities are key factors for HCV entry into hepa-
tocytes. Indeed, HCV entry is a multistep process involving the
interactions of both viral and cellular components of the LVPs
with several host cell receptors. The initial attachment of the
virus to the cell is likely mediated by glycosaminoglycans (14),
by the LDL receptor (15), and/or by the scavenger receptor BI
(SR-BI) (16), which all bind apolipoproteins incorporated on
the surface of viral particles. Then, a complex interaction
between viral glycoproteins, SR-BI, and other cellular host fac-
tors such as the CD81 tetraspanin (17) and the tight junction
proteins Claudin-1 (18) and Occludin (19) allows entry and
internalization of the viral particles (20). Moreover, other pro-
teins implicated in cholesterol uptake such as Niemann Pick
C-1-like 1 (21), and host cell kinases such as the epidermal
growth factor receptor and the ephrin receptor A2 (22) have
been identified as cofactors of HCV entry. Using the HCVcc
and HCV pseudoparticle models, our laboratory recently dem-
onstrated that SR-BI mediates entry of particles independently
of their density via its capacity to transfer lipids to and from
different carriers (23, 24). Finally, presumably at a further step
of entry, HCVcc particles of lower-intermediate density (i.e.
1.08–1.13 g/ml) andHCV pseudoparticles become able to bind
SR-BI via a direct interaction with the E2 glycoprotein, which
results in enhancement of their entry process (23–25).
HCV assembly and release have mainly been studied using
the highly infectious molecular clone JFH1 or using JFH1-de-
rived recombinant viruses produced in hepatoma cell lines
(26–29). However, most of these cell lines have impaired pro-
duction of VLDL because they express pre-VLDLs that are not
fully lipidated and that do not fuse with apoE-containing lumi-
nal lipid droplets (30). The resulting HCVcc particles are thus
poorly associated with apoB (9), and their buoyant density pro-
file is significantly different compared with in vivo recovered
viruses (31, 32). As lipid and apolipoprotein components are
key factors influencingHCVbiology, this highlights the need to
better understand how they are distributed within the different
forms of HCV particles circulating in vivo and how such distri-
butions functionally influence their entry properties. Impor-
tantly, HCV particles from infected patients are not or not
robustly infectious ex vivo, thus precluding their functional
characterization.
A major advance in the study of HCV infection in vivo was
made due to the development of immunodeficient mice that
sustain human hepatocyte engraftment (33, 34). Using the Alb-
uPA/SCID mouse model, Lindenbach et al. (31) showed that
HCV physical particles, as assessed by viral RNA distribution,
have a lower density compared with HCVcc particles; however,
the infectivity of such viral populations remained undermined.
Although this study suggested that viruses issued from infected
mice may have a higher specific infectivity compared with in
vitro cultured virus (31), to our knowledge, there is no study
describing the composition (in terms of viral and cellular com-
ponents) of HCV particles issued from these mice as well as
their entry properties.
Here, we characterize HCV particles and viral subpopula-
tions produced in humanized liver mice derived from the FRG
mouse model (further designated HCVfrg), a triple mutant
mouse knocked out for fumarylacetoacetate hydrolase (FAH),
RAG2, and c (35) that was previously shown to support HCV
infection (36). We demonstrate that, unlike HCVcc, the most
infectious in vivo recovered HCVfrg particles are highly
enriched in apoE. Moreover, our work features further differ-
ences between HCVfrg and HCVcc because we show that
HCVfrg particles exhibit a strongly increased dependence on
SR-BI expression levels for entry of HCVfrg particles of very
low density. Finally, we show that entry of HCVfrg particles of
all densities is strongly dependent on the lipid transfer activity
of SR-BI rather than on its binding to the viral glycoprotein E2.
Thus, altogether, our results suggest that the lipoprotein com-
ponents incorporated on viral particles play a crucial role in
entry of infectious particles, and our results highlight the pow-
erfulness of this in vivo model for the functional study of the
interplay between HCV and liver components.
Experimental Procedures
Cell Lines—Huh-7.5 and 293T cells were grown in DMEM
(Invitrogen) supplemented with 100 units/ml penicillin, 100
g/ml streptomycin, and 10% fetal bovine serum.
Mouse Colony Maintenance, Nitro-4-trifluoromethyl Benzo-
ylcyclohexanedione (NTBC) Cycling, and PrimaryHumanHep-
atocyte (PHH) Engraftment—FRG (Fah/Rag2/Il2rg/)
mice (mixed background: C57BL/6 and 129Sv) were provided
by M. Grompe (Oregon Health and Science University) and
bred in our animal facility (Plateau de Biologie Expérimentale
de la Souris, Lyon, France).
FRG mice are deficient for the FAH enzyme, which leads to
an accumulation of a toxic tyrosine catabolite in the liver. To
prevent this toxicity, mice are maintained on 8 mg/liter NTBC
(Swedish Orphan Biovitrum) in the drinking water. NTBC acts
by blocking the tyrosine catabolic pathway upstream of FAH
and thus prevents the accumulation of toxic metabolites. FRG
mice were kept in temperature- and humidity-controlled ani-
mal quarters with a 12-h light/12-h dark cycle.
PHHs were injected intrasplenically as described previously
(34). Immediately after engraftment, the NTBC was progres-
sivelywithdrawn as follow: 2 days at 10%of colonymaintenance
concentration, then 2 days at 5%, and 2 days at 2.5%, and then
the NTBC was completely removed. During the phase without
NTBC, mice were weighed every 2 days. After 2–6 weeks, mice
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with clinical symptoms (lethargy and hunched posture) or
severe weight loss (15%) were again put on NTBC for 3 days
before a second withdrawal (cycling). Cycling was repeated
until clinical symptoms resolved. To prevent the development
of a murine hepatocellular carcinoma, highly reconstituted
mice selected for infectious experiments were subjected to fur-
ther NTBC treatment (3–4 weeks without NTBC and 3 days
with 100% NTBC). No other drugs were administered during
the entire study. 48 h prior to engraftment, adult (6–10 weeks
old) mice were injected intravenously with 2  109 pfu of an
adenoviral vector encoding the uPA transgene. 7  105–1 
106 PHHs (BD Biosciences) were injected intrasplenically, and
NTBC was progressively withdrawn. Experiments were per-
formed in accordance with the European Union guidelines
for approval of the protocols by the local ethics committee
(Authorization Agreement C2EA-15, Comité Rhône-Alpes
d’Ethique pour l’Expérimentation Animale, Lyon, France).
Immunohistochemistry Antibodies and Methods—For histo-
logical examination, liver tissues from FRG mice were fixed in
10% buffered formalin and embedded in paraffin. 4-m-thick
sections were prepared according to conventional procedures,
stained with hematoxylin-phloxine-saffron, and observed with
a light microscope. Immunohistochemistry was performed
using a panel of primary antibodies against FAH (Aviva Systems
Biology, SanDiego, CA), carcinoembryonic antigen (Novus Bio-
logicals, Littleton, CO), CD31, CD34, CK7, and CK18 (all from
Dako, Glostrup, Denmark). These antibodies only reacted with
human tissue.
An automated immunostainer (Ventana Discovery XT,
Roche Applied Science) was used with the DABmap kit accord-
ing to the manufacturer’s instructions. A standard horseradish
peroxidase staining procedure was followed. All sections were
counterstained with Gill’s hematoxylin. As negative controls,
slides were stained without the primary antibody. Slides were
analyzed in a Mirax slide scan (Zeiss, Jena, Germany).
The repopulation index was determined by using an ImageJ
macro program. Images were split into their color components
based on 3,3-diaminobenzidine staining (color deconvolution),
then automatically thresholded, and measured. Results were col-
lected in a comma-separated value table. The repopulation index
was calculated based on the surface ratio between the 3,3-di-
aminobenzidine-positive surface and the total surface.
Serological and Immunohistochemical Analyses—Blood
from transplanted mice and controls was collected every 2–4
weeks after engraftment by retro-orbital puncture. Sera were
sent to a diagnostic laboratory for quantification of human
serum albumin (Cobas C501 analyzer, Roche Applied Science).
For lipoprotein analyses, sera were run on a Lipoprint Lipopro-
tein Subfractions Testing System (Quantimetrix) that quanti-
fies lipoprotein fractions (VLDL, LDL, andHDL) on the basis of
their cholesterol amount. Human apoB and apoE concentra-
tions weremeasured in FRGmouse sera and human samples by
ELISA (Mabtech, Sweden) according to the manufacturer’s
instructions.
HCVcc Production—In vitro transcribed RNAwas electropo-
rated into Huh-7.5 cells. 72 h postelectroporation, infectious
titers were determined as focus-forming units (FFU)/ml esti-
mated by NS5A immunostaining and colony counting as
described previously (37). Infectious titers were between 1 and
2 105 FFU/ml.
Virus Inoculation and Blood Analysis—Highly reconstituted
mice (human serum albumin (HSA)15mg/ml) were infected
with 1 105 FFU ofHCVof genotype 2a of the Jc1 chimera (29)
by the intraperitoneal route. 100l of total bloodwere collected
every week, andHCVRNA and viral infectivity weremeasured.
RNA was extracted with a guanidine thiocyanate method,
reverse transcribed (iScript cDNA synthesis kit, Bio-Rad), and
quantified with the FastStart Universal SYBR GreenMaster kit
(Roche Applied Science) on an Applied StepOne Real-Time
PCR apparatus using HCV-specific primers (5-TCTGCGGA-
ACCGGTGAGTA and 5-TCAGGCAGTACCACAAGGC).
As an internal control of extraction, an exogenous RNA from
the linearized Triplescript plasmid pTRI-Xef (Invitrogen) was
added into the sera prior to extraction and quantified with spe-
cific primers (5-CGACGTTGTCACCGGGCACG and
5-ACCAGGCATGGTGGTTACCTTTGC).
Iodixanol Gradient Separation of HCV Particles—800 l of
serum from infectedmice or HCVcc virus-containing superna-
tants were loaded on top of a 3–40% continuous iodixanol gra-
dient (Optiprep, Axis Shield). Gradients were centrifuged for
16 h at 4 °C in an Optima L-90 centrifuge (Beckman).
Co-Immunoprecipitation (Co-IP) of Apolipoproteins and
Viral RNA—Co-IPs of apolipoprotein-HCVRNA fromHCVfrg
and HCVcc were performed on 100 l of non-fractionated
samples or on iodixanol-separated fractions. Samples were run
in a 3–40% iodixanol gradient. Seven fractions of 1500 l were
collected from the top of the gradient, and 1100l were used for
co-IP experiments. Samples were precleared with 40 l of pro-
teinGmagnetic beads (Millipore) for 1 h at 4 °C. For preabsorp-
tion of antibodies to protein G magnetic beads, 6 l of poly-
clonal goat anti-apoE (AB947, Millipore) or anti-apoB (AB742,
Millipore) or goat immunoglobulins (IP control) were mixed
with 40l of beads in a total volume of 100l and incubated 1 h
at 4 °C. The precleared samples were added to the antibody-
coated beads and incubated for 3 h at 4 °C under continuous
rotation. The immune complexes were washed three times in
PBS, and beads were resuspended in guanidine thiocyanate
buffer for HCV RNA extraction and quantification or alterna-
tively in lysis buffer for Western blot analysis.
Establishment of Cell Lines Expressing WT or Mutant
SR-BI—Retroviral vectors expressing human SRBI (hSR-BI),
mouse SR-BI (mSR-BI), or the hSR-BI point mutant G420H/
G424H were generated and expressed in Huh-7.5 cells as
described previously (24). Down-regulation of hSR-BI was
achieved using two small interfering RNAs (5-GCAGCAGG-
UCCUUAAGAAC and 5-GGCACTGTTCTGGAACCTTC)
as described previously (38). SR-BI overexpression was verified
by FACS analysis (CLA-1 antibody, BD Pharmingen) or by
Western blot analysis (NB400-104 antibody, Novus).
Neutralization Assays—Huh-7.5 cells overexpressing hSR-BI
were preincubated with the anti-SR-BI antibody NK-8H5-E3
(39) or with control IgGs for 1 h at 37 °C at a final concentration
of 10 or 100 g/ml. Cells were then infected with dilutions of
non-fractionated viruses or with gradient density-separated
fractions of HCVfrg and HCVcc particles. Infectivity was mea-
sured 72 h postinfection by immunostaining the viral glycopro-
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tein E2 using the human recombinant AR3A antibody (Ref. 40;
a kind gift fromM. Law).
Results
FRGMice withHighly ReconstitutedHuman Liver Allow Pro-
ductive HCV Infections—We first sought to validate that, in our
experimental conditions, engraftment of FRG mice with pri-
mary human hepatocytes allows a robust liver reconstitution
and thus a sustained HCV infection as described previously
(36). 11–16 weeks postengraftment, HSA levels were higher
than 15 mg/ml (range, 16–29 mg/ml) in 65% of the engrafted
mice, i.e. close to the human physiologic concentrations (Fig.
1D). Human FAH immunostaining in liver sections confirmed
a high and homogeneous repopulation with PHHs (Fig. 1A)
with a good correlation between HSA values and the extent of
human liver reconstitution (Fig. 1E). Overall, in 76% of the
mice, liver repopulation with PHHs was higher than 40%. Next,
we investigatedwhether highly human liver-reconstitutedmice
were able to secrete human lipoproteins. Mice rely on HDL for
their cholesterol supply, whereas in humans, LDL and VLDL
FIGURE 1. Highly repopulated liver chimeric mice sustain HCV infection. A, human FAH staining of a moderately liver-reconstituted mouse, a highly liver-
reconstitutedmouse, and non-engraftedmouse. R.I., repopulation index.Original magnifications,15 and400 (insets). B, lipoprotein distribution in the sera from
FRG mice reconstituted at different levels as indicated by HSA levels in mg/ml and human sera or non-engrafted FRG mouse sera as control. Sera were run on a
Lipoprint system, and cholesterol content was measured within each lipoprotein fraction. Results represent the percentage of cholesterol in each subpopulation
comparedwith total cholesterol.C, quantificationofhumanapoBandapoE in theserumofhuman liver-reconstitutedmice,human individuals, andsupernatant from
confluentHuh-7.5 cells. Statistical analyseswereperformedbyaMann-Whitney test.N.S., not statistically significant.D, followupofHSA inhuman liver engraftedFRG
mice (id 1–12). As a comparison, HSA was measured in plasma or sera from three healthy individuals (Donors 1–3). To note, HSA levels in engrafted mice are in
accordance with a recently published study on humanized liver in NOD FRGmice (65). E, correlation between HSA and the repopulation index that represents the
percentage of human FAH-positive cells in liver sections fromPHH-engrafted FRGmice. h, human;w, week;HuHep, human hepatocytes.
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are the preponderant cholesterol-supplying lipoproteins.
Accordingly, the determination of the LDL versusHDLpropor-
tion revealed that although sera from mice with low levels of
human liver reconstitution are enriched with high density lipo-
proteins the profiles of highly human liver-reconstituted mice,
as assessed by HSA levels, approached the human profiles, i.e.
characterized by a preponderance of low density lipoproteins
(Fig. 1B). Finally, highly liver-reconstituted FRG mice (HSA
15mg/ml) secreted high levels of human lipoproteins close to
human physiological concentrations (Fig. 1C). The histological
analyses of human liver-reconstituted mice further confirmed
that highly repopulated chimeric livers had a normal and func-
tional liver architecture in which human hepatocytes of differ-
ent degrees of maturation as well as a human bile canalicular
network and sinusoid vessels were observed (Fig. 2).
Engraftedmice withHSA levels over 15mg/ml were infected
with 105 FFU of HCVcc of genotype 2a (Jc1 chimera). The
amount of HCV RNA detected in the sera increased steadily over
timeafter infection to reachaplateau level at approximately 7days
postinoculation as described previously (36), and HCV infection
was robust and sustained in all of the inoculated mice with both
viral RNA (range, 105–108 genome equivalents (GE)/ml) and
infectious particles (range, 103–106 FFU/ml) being detected for at
least 4weeks (Fig. 3A). Importantly,HCVfrg viral loadswere com-
parable with HCV RNA titers measured in infected individuals in
acute phase (range, 5 104–5 108 GE/ml) (41).
HCVfrg Infectious Particles Have a Lower Density as Com-
pared with HCVcc—Four weeks after infection, animals were
sacrificed, and total blood was collected. Infected sera were
loaded on continuous density gradients and separated in 15
fractions. Viral RNA and infectious virus levels were deter-
mined for each fraction. Buoyant density analysis revealed
the distribution of HCVfrg RNAwithin twomajor RNA pop-
ulations (Fig. 3B), the first in the 1.06–1.11 g/ml density
range and the second in the 1.11–1.16 g/ml density range.
Interestingly, the viral RNA population of lower density
overlapped with the infectious population (Fig. 3B), showing
that most of the infectious virus (90%; range, 80–100%)
had a density between 1.06 and 1.11 g/ml, whereas a large
amount of physical particles, i.e. those of higher density, was
not or very poorly infectious.
As a comparison, similar fractionation experiments were
performed usingHCVcc, and they raised important differences
compared with HCVfrg particles. Indeed, we found that the
buoyant density of the HCVcc infectious viral population was
more heterogeneous as compared with HCVfrg (Fig. 3C).
Indeed, 90% of HCVcc infectious particles were distributed
among density fractions of 1.03–1.13 g/ml in contrast to the
more restricted range of density of infectious HCVfrg (i.e. 90%
in density fractions of 1.06–1.11 g/ml). Furthermore, the high-
est infectivity of HCVcc infectious particles was shifted among
higher density fractions (1.08–1.13 g/ml) with a peak around
1.10 g/ml (Fig. 3C), whereas most physical particles were
detected within fractions of 1.10–1.15 g/ml with a peak around
1.12 g/ml (Fig. 3C). Interestingly, viruses recovered in vivo had
a approximately 100-fold augmentation in their specific infec-
tivity (HCVfrg, 5.3  102 FFU/GE; HCVcc, 4.2  104 FFU/
GE) as calculated by the median of the specific infectivity of
each HCVfrg and HCVcc sample (Fig. 3, B and C, insets). Alto-
gether, these results indicated that in vivo produced infectious
HCVfrg particles are highly infectious and have a lower and
more homogenous density as compared with cell culture-de-
rived virus. These differences of biophysical properties imply
that HCVfrg and HCVcc likely differ in terms of lipid and/or
protein composition.
Highly Infectious HCVfrg Populations Are Enriched with
ApoE—Therefore, we sought to determine whether the differ-
ence in density profiles betweenHCVfrg andHCVcc infectious
particles was due to a differential association of the virus with
lipoprotein components. To separate viral particles from lipo-
proteins, we performed co-IP assays using antibodies against
apolipoproteins apoE and apoB, andwe quantified the captured
particles by HCV RNA-specific RT-quantitative PCR. We
decided to use this approach because previous papers showed
that the initial capture of viral particles with anti-E2 antibodies
was inefficient probably because of poor epitope accessibility
(9, 10). We first performed co-IP assays on non-fractionated
samples using apoE or apoB antibodies.We could immunopre-
cipitate 57% (mean 29%; n 7) and 30% (mean 20%; n 9)
of HCVcc viral RNA using anti-apoE- and anti-apoB-coated
beads, respectively. In contrast, we could co-immunoprecipi-
tate 23% of total HCV RNA of HCVfrg particles with apoE
antibodies (mean  20%; n  10) but less than 5% with apoB
(mean  5%; n  8) antibodies (data not shown). The weak
apoB capture of HCV particles from HCV-infected human
liver-reconstituted FRG mouse samples is likely to depend
on the high concentration of apoB in the sera of human
liver-reconstituted FRG mice (Fig. 1C), which may compete
with apoB present on viral particles for the binding to the anti-
body. Indeed, addition of serum from non-infected human liver-
reconstituted FRG mice to HCVcc particles decreased the co-IP
rates by about 10-fold (data not shown).Moreover, the dissimilar-
ities in co-IPs results of HCVfrg versusHCVcc particles could be
due to a different lipidation of either type of viral particle and thus
to a differential exposure of apoE and apoB proteins on their
surface.
We then performed co-IPs of apoE-HCV RNA on density
gradient-separated viral subpopulations. First, we sought to assess
the distribution of apoE along the different buoyant density-sepa-
rated fractions. Although the distribution of apoE inHCVcc sam-
ples was homogeneous among the different subpopulations (Fig.
4B), apoE was predominantly present in low density fractions of
HCVfrg samples (i.e. 	1.06 g/ml) (Fig. 4A). Nevertheless, apoE
could be readily immunoprecipitated all along the gradient for
both HCVcc and HCVfrg samples (Fig. 4,A and B).
To verify that this differencewas due to a different lipid com-
position of mouse sera versus cell culture supernatants and not
to viral components, uninfected mouse sera were subjected to
gradient density separation, and apoE distribution was ana-
lyzed by Western blot analysis. The results showed a similar
distribution of apoE among fraction samples derived from
HCV-infected or uninfected mouse sera (Fig. 4, A and C), thus
confirming a different composition of lipoproteins between the
HCVfrg and HCVcc models.
Interestingly, when comparing apoE-HCV RNA co-im-
munoprecipitation in HCVfrg versus HCVcc samples sepa-
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rated on density gradients, we found that although for
HCVcc particles (Fig. 4E) apoE-enriched particles were dis-
tributed throughout the gradient without marked overlap
with infectious populations the distribution of apoE-co-im-
munoprecipitated HCVfrg particles coincided with the
highly infectious population (i.e. at a density range of 1.06–
1.11 g/ml) (Fig. 4D). To rule out that the quantity of antibody
was limiting for the immunoprecipitation of highly apoE-
enriched fractions, we performed co-IP assays with a 10
times greater quantity of antibody than we otherwise used
FIGURE 2.Highly repopulated chimeric livers maintain a normal and functional liver architecture. A, hematoxylin-phloxine-saffron staining reveals that
liver parenchyma is repopulated by pale human hepatocytes. Human hepatocyte aggregates are easily discerned after hematoxylin-eosin staining because of
their large size, abundant cytoplasm, and large nuclei containing dispersed chromatin with well formed nucleoli. B, immunodetection of human-specific
carcinoembryonic antigen confirms the capacity for human hepatocytes to form bile canaliculi; the bile canalicular network is as dense and organized as in
normal human liver. C, human hepatocytes are also detected with anti-human CK18. Mature human hepatocytes present a pale staining, whereas human
hepatic progenitor cells are strongly immunoreactive for CK18. The black arrow indicates human hepatic progenitors. D, staining with anti-human CK7
confirms the presence of immature hepatocytes (white arrow), which are surroundedbymature hepatocytes that do not stain for CK7. After immunodetection
of CK18 andCK7 (C andD), it is possible to identify humanbile ducts cells (CK7
) andCK7
/CK18
 small to intermediate sized cellswithmoderately abundant
cytoplasm and excentered nuclei; they are similar to the so-called intermediate cells observed during human liver regeneration after injury or cell loss.
Anti-human CK7 also stains human bile ducts cells (black arrow). E, within human hepatocyte aggregates, cells are arranged in plates of variable thickness
separated by well formed sinusoid vessels lined by CD31
 or CD34
 (inset) endothelial cells. F, the presence of a few Ki67-positive cells, preferentially at the
junction between human and murine hepatocytes, indicates proliferation of human hepatocytes in close proximity to dying murine hepatocytes. Original
magnifications,400 (200 for A and400 for inset). Scale bar, 100 m (200 m for A and 100 m for inset). H, human hepatocytes;M, murine hepatocytes;
VCL, centrolobular vein; P, portal track.
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for such experiments (as in Fig. 4D), and we found that the
distribution of the co-immunoprecipitated apoE-HCV RNA
complexes had the same profile regardless of the apoE anti-
body concentration (data not shown).
Thus, in sharp contrast with HCVcc, apoE was reproducibly
enriched in specific HCVfrg populations representing themost
infectious particles. This reflected the homogeneity of HCVfrg
infectious particles. In accordance with the in vitro studies of
FIGURE 3. Highly infectious HCVfrg populations have a lower density compared with HCVcc viral particles. A, time course quantification of HCV RNAs and
infectious virus levels in mice sera after inoculation with 105 FFU of Jc1 virus (HCV2a genotype). HSA levels at the time of the inoculation are reported in the chart
legend. HCV RNA and infectious viruses were not detected at any time points in the controls (i.e. engrafted mice with mock inoculation and non-engrafted mice
inoculatedwithHCV;datanot shown). Thedetection limitsof thequantificationofHCVRNAand infectivity are2104GE/mland5102FFU/ml, respectively.B, sera
fromhumanized liverFRGmice.Becauseof the limitedvolumeof serumavailable fromeachmouse, theywerepooled twobytwotoobtainahigh resolutiongradient
with several fractions. Numbers indicate mice identification numbers. C, supernatants from HCVcc-infected Huh-7.5 cells. Three independent experiments were
performed(JC11–3). Sampleswere runovernight ina3–40%iodixanolgradient. Fifteen fractionswerecollected,andHCVRNAand infectivityweremeasured.Results
are reported as the percentage of RNA or infectivity in each fraction relative to the total. In HCVfrg (B), RNA (top graph) is distributed in twomain populations with a
density of 1.06–1.11 and 1.11–1.16 g/ml (defined by yellow and green boxes, respectively), whereas infectivity (bottom graph) is uniformly distributed within one
population (yellowbox) of 1.06–1.11g/ml. InHCVcc (C), RNA (topgraph) ismainlydistributedaround the fractionswithadensityof 1.10–1.15g/ml (bluebox),whereas
infectivity (bottom graph) is mostly detected in fractions of 1.08–1.13 g/ml (orange box). Insets, specific infectivity expressed as the number of infectious particles/
physical particles (ratio FFU/GE). The horizontal bars represent themedian values. HCVfrg, n 9; HCVcc, n 3.
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apoE function, our findings suggested that apoE is an essential
factor for entry of infectious in vivo produced virus (23, 42–46).
HCVfrg Show an Uneven Dependence on SR-BI for Entry of
Viral Subpopulations—Previous results from our laboratory
indicated that specific functions of SR-BI are implicated in
entry of HCVcc subpopulations in a manner dependent on the
physicochemical properties of the viral particles (23). Impor-
tantly, the comparison of HCVfrg and HCVcc particles high-
lighted substantial dissimilarities in the apoE content of the
different viral particle subpopulations (Fig. 4). Because apoE
incorporated on virions acts as a ligand of SR-BI for HCV entry
into cells (23, 42), we first sought to investigate the reliance on
SR-BI for entry of HCVfrg subpopulations.
Thus, we modulated expression of human SR-BI in Huh-7.5
cells (Fig. 5A) to determine infectious titers and SR-BI depen-
dence of HCVfrg subpopulations. We found that infectivity of
non-fractionated HCVfrg as well as of HCVcc (Fig. 5, B and C)
particles was decreased and increased by about 10 times in
SR-BI down- and up-regulated cells, respectively. This indi-
cated that, similarly to HCVcc, HCVfrg particles rely on SR-BI
for entry into cells.
Consistently, in fractionated HCVfrg and HCVcc samples,
SR-BI down-regulation resulted in a pronounced and uniform
diminution of infectivity (Fig. 5, D and E) regardless of their
density, thus confirming the importance of this receptor for
entry. Moreover, SR-BI overexpression stimulated entry of
both HCVfrg and HCVcc subpopulations (Fig. 5, D–F), partic-
ularly those that exhibited the highest infectivity (i.e. in frac-
tions 1.06–1.11 and 1.08–1.13 g/ml, respectively). Interest-
ingly, in sharp contrast to HCVcc, gradient density-separated
HCVfrg viral subpopulations showed an uneven dependence
on SR-BI for entry. Indeed, the effect of SR-BI overexpression
on HCVfrg infectivity was specifically marked in the very low
density fractions (Fig. 5F). This was particularly salient for
HCVfrg particles of density 	1.05 g/ml for which at least
10–100-fold higher infectious titers could be detected (Fig. 5,D
and F). This indicated that SR-BI expression is limiting for entry
of low density HCVfrg particles, which highlighted a further
difference between HCVfrg and HCVcc.
To confirm SR-BI dependence for entry of HCVfrg viral sub-
populations, cellswere incubated prior to infectionwith the SR-BI
antibody NK-8H5-E3 that has been shown previously to block
FIGURE 4.Highly infectiousHCVfrgparticles are enriched in apoE. The distributions of apoE in buoyant density-separated fractions of HCVfrg (A), HCVcc (B)
samples, and serum of an uninfected FRG mouse (C) are shown. 50 l of each fraction as well as their respective apoE-immunoprecipitated complexes were
lysed in a denaturing buffer and stained with a polyclonal goat anti-apoE antibody (AB947). In A and C, the upper panel corresponds to a high film exposure,
whereas the lower panel corresponds to a low exposure. As a control for unspecific binding, non-fractionated HCVfrg and HCVcc samples were subjected to
immunoprecipitation with goat IgG-coatedmagnetic beads (IgG Ctrl). The distributions of infectivity and of co-immunoprecipitated complexes of apoE-HCV
RNA in buoyant density-separated HCVfrg (D) and HCVcc (E) are shown. ApoE IP values are calculated as a percentage of co-immunoprecipitated RNA relative
to the total RNA within each fraction using an equivalent volume for each fraction. JC1 1–4 are from four independent experiments.
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FIGURE 5. SR-BI expression differentially modulates entry of HCVfrg and HCVcc viral subpopulations. A, flow cytometry analysis of Huh-7.5 cells over-
expressing (OE) or down-regulating (DR) SR-BI at the time of HCV infection. Huh-7.5 cells were transduced with two bicistronic lentiviral vectors coding small
interfering RNAs (SR-BI/siRNA-2 and SR-BI/siRNA-24) together with the GFP protein (DR SR-BI, down-regulation of SR-BI) or with a lentiviral vector coding
human SR-BI (OE SR-BI, overexpression of SR-BI). CTRL, cells transducedwith the backbone vector expressing theGFP;NT CTRL, non-transduced cells; STN CTRL,
staining without the primary antibody. Transduced cells were infected with serial dilutions of sera from non-fractionated HCVcc-infected mice (B) or of
supernatants from HCVcc-infected Huh-7.5 cells (C). As a control, cells were transduced with the backbone vector expressing the GFP. Infection levels were
within a range of 1.3  104–3.9  104 FFU/ml and 2.2  104–5.3  104 FFU/ml for HCVfrg and HCVcc, respectively. Statistical analysis was performed by
Student’s t test (n  3). SR-BI down- or up-regulated cells were infected with HCVfrg (D) or HCVcc (E) using serial dilutions of gradient density-separated
fractions. Examples of distribution of infectivity from two humanized liver FRGmice (D) and from two HCVcc independent experiments (E) are shown. F, -fold
increase of infectivity of HCVfrg andHCVcc subpopulations in hSR-BI-overexpressing cells comparedwith the controls. Results are the averageof sevenHCVfrg
and six HCVcc independent experiments and are shown for each density fraction (F1–F15). Statistical analyses were performed by a Mann-Whitney test. N.S.,
not statistically significant. Error bars represent S.D.
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HCVcc entry (39). In non-fractionated samples, blocking of SR-BI
caused a marked decrease of infectivity of both HCVfrg and
HCVcc samples in a dose-dependent manner (Fig. 6, A and B).
Moreover, the SR-BI antibody strongly reduced infectivity of all
viral subpopulations forbothHCVfrgandHCVccviruses (Fig. 6,C
andD), confirming their usage of SR-BI for entry into cells.
HCVfrg Entry Depends Mostly on the Lipid Transfer Activity
of SR-BI—Next, to investigate how SR-BI allows HCVfrg entry,
we determined the infectivity of HCVfrg subpopulations (and
ofHCVcc for comparison) onHuh-7.5 cells expressing, in addi-
tion to the endogenous SR-BI, the murine ortholog mSR-BI
(Fig. 7A), which does not bindHCVE2 (23, 47). Overexpression
of either human or murine SR-BI significantly increased infec-
tivity of both HCVcc and HCVfrg particles (Fig. 7, C and D),
which indicated that SR-BI promotes HCV entry indepen-
dently of E2 binding. Consistently, despite similar levels of
overexpression of human and murine SR-BI (Fig. 7A), mSR-BI
overexpression led to an augmentation of infectivity for all
HCVfrg and HCVcc fractions (Fig. 7, E and F). Moreover, sim-
ilarly to hSR-BI, overexpression of mSR-BI markedly increased
infectivity of HCVfrg particles of very low density (	1.05 g/ml)
(Fig. 7, E andG). Thus, altogether, these results highlighted the
role of SR-BI for entry of in vivo derived particles and indicated
thatmodulation of entry by SR-BI is independent of its capacity
to bind to HCV E2.
Themain physiological function of SR-BI is to transfer lipids
between lipoproteins and cells (48), a function that is pivotal for
HCVcc cell entry (23, 24, 47). We thus investigated the impact
of the overexpression of the G420H/G424H hSR-BI mutant,
which has impaired capacity to transfer lipids despite normal
HDL binding capacity (49), on infectivity of HCVfrg and
HCVcc subpopulations. Interestingly, we found that, despite
comparable levels of cell surface expression of mutant and wild-
type hSR-BI (Fig. 7, A and B), the overexpression of the G420H/
G424H mutant in Huh-7.5 cells still expressing the endogenous
SR-BI did not induce increased cell entry of either HCVfrg or
HCVccparticleswhencomparedwithoverexpressionofwild-type
hSR-BI regardless of their density (Fig. 7, C–G). Altogether, these
results highlighted that, among the different functions of SR-BI in
HCV entry, the principal factor that promotes entry of HCVfrg
particles is linked to its capacity to transfer lipids.
Discussion
Many aspects of HCV biology are not completely resolved
because of the lack of convenient animalmodels that could repro-
duceHCV infection and replication. An early study performed on
FIGURE 6. SR-BI antibody blocks entry of HCVfrg and HCVcc viral subpopulations. Cells overexpressing hSR-BI (Fig. 5A) were preincubated with the indicated
concentrations of the NK-8H5-E3 SR-BI-blocking antibody (Anti-SR-BI) or a control isotype (CTRL IgG). Cells were subsequently infected with serial dilutions of non-
fractionated sera from HCVcc-infected mice (A) or non-fractionated supernatants from HCVcc-infected Huh-7.5 cells (B). Infection levels in the absence of antibody
werewithin a rangeof 3.4 103–1.5 104 and 6.7 104–1.8 105 FFU/ml for HCVfrg andHCVcc, respectively. Statistical analysiswas performedby Student’s t test
(n 3). N.S., not statistically significant. Error bars represent S.D. SR-BI-up-regulated cells were preincubated with the NK-8H5-E3 antibody (Anti-SR-BI) or a control
isotype (CTRL IgG). Cellswere then infectedwithHCVfrg (C) or HCVcc (D) using serial dilutions of gradient density-separated fractions. Representative distributions of
infectivity from two humanized liver FRGmice (C) and from twoHCVcc (D) independent experiments are shown. Ab, antibody.
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chimpanzees demonstrated that the low density viral subpopula-
tionsrecovered invivowere themost infectiouswhenreinoculated
in other animals (50). However, the interpretation of these results
was limitedby the fact that viral particles issued fromchimpanzees
contained anti-HCV antibodies that could have altered the intrin-
sic biophysical properties and infectivity of these particles. The
development of immunodeficientmousemodels with humanized
livers that could sustainHCV infectionwas a great step forward to
the understanding ofHCVbiology.Here, by using the FRGmouse
model,wecharacterized thephysicochemical and infectiousprop-
erties of viral particles issued from humanized liver mice. We
showed that infectious particles produced in vivo have a lower
density comparedwithHCVccparticles and that ahigh amountof
non-infectious particles with higher density circulate in the blood
of these animals. Because we and others (51) have demonstrated
that FRGmice have a humanized lipoprotein profile, we can spec-
ulate that the lowdensityprofile of the infectiousparticles is due to
adifferent lipid and/orprotein content comparedwith theHCVcc
model.
To better characterize HCV particles issued from the FRG
model, we investigated their apolipoprotein composition. Viral
particle capture with apoB antibodies resulted in co-immuno-
precipitation of 30% of HCVcc RNA and of less than 5% of
HCVfrg RNA. The presence of apoB in viral particles issued
from Huh-7.5 cells is still a matter of debate. Although some
studies have indicated that apoB is dispensable for production
of infectious particles (52) and is barely detected in viral parti-
cles derived from Huh-7.5 (9, 53), other studies have revealed
its importance in HCV assembly and maturation (1, 11, 54).
Moreover, the presence of apoB on secreted HCV particles has
been demonstrated in viruses derived from cultured primary
hepatocytes (32) or from long term cultures of Huh-7.5 cells
differentiated with human serum-containing culture media
(55) and in viruses recovered from patients (7, 8). However, in
most studies, rather than direct apoB-HCV RNA co-immuno-
precipitation, othermethods such as affinity grid immunolabel-
ing of apoB in precaptured tagged viruses or capture by anti-
body of immunoglobulin-LVP complexes followed by apoB
quantification by ELISA were used (7, 8, 10). Our results using
non-fractionated as well as density gradient-fractionated sera
(data not shown) from infectedmice suggest thatHCVparticles
produced in vivo are not as accessible as HCVcc for capture
with anti-apoB antibodies. As mentioned above, our co-IP
experiments with HCVcc alone or mixed with sera from non-
infected human liver-reconstituted FRG mice suggested that
the high amount of human apoB present in the sera of these
mice could compete with apoB incorporated on HCVfrg parti-
cles for the binding to the antibody. In accordance, human apoE
and apoB concentrationswere 2 logs higher in sera fromhuman
liver-reconstituted FRG mice as compared with supernatant
from the in vitro HCV culture cell model (Fig. 1C). Moreover,
we can speculate that HCVfrg particles, unlike HCVcc, are fully
lipidatedandthat their lipid layerwouldmaskapoBepitopes,mak-
ing theminaccessible toanti-apoBantibodies.This concept is con-
gruent with previous findings fromNielsen et al. (8) showing that
treatment of purified LVPs in mild detergent conditions changes
the apolipoprotein composition of viral particles.
In HCVfrg subpopulations, the distribution of the apoE-en-
riched viral particles clearly overlapped with the peak of infec-
tivity, suggesting that this apolipoprotein plays a major role for
entry of in vivo derived particles. On the contrary, for HCVcc
particles, apoE co-immunoprecipitated with HCV RNA in all
fractions irrespective of their infectious properties, indicating
that a high proportion of apoE-containing particles issued from
in vitro cultures are poorly infectious. This could reflect an
improper maturation of lipoproteins (and thus of viral parti-
cles) in Huh-7.5 cells (30), which would not allow a correct
incorporation and/or folding of apolipoproteins into lipopro-
teins and thus HCV particles. Alternatively, we could surmise
that the physicochemical composition of HCVfrg particles
retrieved from peripheral blood could be modified by periph-
eral lipoprotein lipases that influence VLDL lipid and apolipo-
protein composition. Indeed, Shimizu et al. (56) showed that
lipoprotein lipase treatment of HCVcc particles resulted in a
decreased infectivity, a shift toward higher density, and a loss of
apoE in viral particles. Finally and in a more general way, it has
been demonstrated that in recombinant HDL complexes the
lipid contentmodulates the stability of apoA-I (57), which indi-
cates that lipid contentmodifications influence the apolipopro-
tein composition of lipoproteins. Thus, modifications of the
lipid content of viral particles may influence the stability of
their apolipoproteins.
HCV entry is a complex mechanism involving multiple cel-
lular receptors. In a previous work, we demonstrated that
among them SR-BI modulates entry of HCVcc subpopulations
depending on their physicochemical properties (23). Because
the initial capture of intermediate density HCVcc particles
involves binding of SR-BI to apoE incorporated on viral parti-
cles and because we have observed a different distribution of
this apolipoprotein in HCVfrg versus HCVcc subpopulations,
we investigated the reliance on SR-BI for entry of HCVfrg sub-
populations. First, we show that HCV particles recovered from
sera of infected mice are dependent on SR-BI for entry because
its down- or up-regulationmodulated infectivity by about 1 log
compared with control cells. These data are in accordance with
Grove et al. (58) who showed that SR-BI up-regulation
FIGURE 7.HCVfrg andHCVccparticles exploit different SR-BI properties for entry dependingon thebiophysical and cellular determinants of the viral
particles. A, Western blot analysis of Huh-7.5 cells overexpressing mouse SR-BI (OEmSR-BI), human SR-BI (OE hSR-BI), or the mutant form of hSR-BI (OE hSR-BI
G420H-G424H) or non-transduced cells as a control. Cell lysates were stained with anti-SR-BI antibody and with anti--actin antibody (AC74, Sigma). B, flow
cytometry analysis ofHuh-7.5 cells overexpressing (OE) thewild typeor theG420H/G424HhSR-BImutant (OEhSR-BI G420H-G424H).CTRL, cells transducedwith
the backbone vector expressing the GFP; STN CTRL, stainingwithout the primary antibody. Huh-7.5 cells overexpressing human SR-BI (OE hSR-BI), mouse SR-BI
(OEmSR-BI), or G420H/G424H hSR-BI mutant (OE hSR-BI G420H-G424H) were infectedwith non-fractionated HCVfrg (C; n 5) or HCVcc (D; n 3) or with serial
dilutions of the gradient density-separated fractions of HCVfrg (E) or HCVcc (F). Infectivity was calculated for equivalent volumes for each fraction. Note that
up-regulated cells and controls express the endogenous SR-BI. Statistical analyseswere performedon total infectivitywith Student’s t test.N.S., not statistically
significant. G, -fold increase of infectivity of HCVfrg and HCVcc subpopulations in mSR-BI- or hSR-BI G420H/G424H-overexpressing cells compared with the
controls. Results are the average of fourHCVfrg and fourHCVcc independent experiments and are shown for eachdensity fraction (F1–F15). Statistical analyses
were performed by a Mann-Whitney test. N.S., not statistically significant. Error bars represent S.D.
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increased by 4-fold the infectivity of sera from HCV-infected
humanized liver uPA/SCID mice.
Importantly, the expression of the murine SR-BI ortholog,
whichdoesnot bindHCVE2 (23, 47), resulted in an augmentation
of infectivity in all of the HCVfrg subpopulations, demonstrating
thatmodulation of entry by SR-BI is independent of its capacity to
bind HCV E2. The expression of the murine SR-BI ortholog
resulted in a greater increase of infectivity of both HCVfrg and
HCVcc particles compared with the overexpression of human
SR-BI. We suggest that, despite the expression of an equivalent
amount of mouse and human SR-BI in transduced cells as shown
byWestern blot analysis (Fig. 7A), mSR-BI could be preferentially
expressed at the membrane surface in Huh-7.5 cells or alterna-
tively that the internalization rate of the virus-receptor complexes
could bedifferent for thehuman versusmurine SR-BI.Overall, the
expression, stability, localization, and interaction with other
receptors and factors that promote HCV entry of mSR-BI or
hSR-BI could be differentially regulated.
Moreover, we show that entry ofHCVfrg particles pertains to
the lipid transfer activity of SR-BI, and our data underscore that
this is a feature required independently of the density of the
particle subpopulations. Thus, our study highlights that entry
of in vivo produced HCV particles is strictly dependent on the
physiological functions of SR-BI and likely on the incorporated
lipoprotein components rather than on the capacity of this
receptor to bind viral surface glycoproteins.
We found that SR-BI expression is a limiting factor for entry
of the most infectious particles for both HCVfrg and HCVcc
models (i.e. of intermediate-high density, 1.06–1.11 and 1.08–
1.14 g/ml, respectively). This observation is consistent with
previous findings that HDLs, which have a density of 1.06
g/ml, are natural ligands of SR-BI that facilitateHCV entry (25).
Within these subpopulations, the increase of infectivity in
HCVcc was significantly higher than in HCVfrg subpopula-
tions. Because we had previously demonstrated that in these
subpopulations SR-BI-mediated entry depends on its interplay
with E2 (23), we can speculate that in HCVcc particles the viral
glycoproteins are more accessible for the binding to SR-BI as
compared with HCVfrg particles. Alternatively, because HDL-
mediated entry enhancement is regulated by E2 (23) and
because the available HDL amounts are likely different for
HCVfrg sera and HCVcc supernatants, such variations might
exacerbate distinct dependence on SR-BI. In accordance, in
cells overexpressingmSR-BI, which does not bind E2, therewas
no difference in the increase of infectivity betweenHCVfrg and
HCVcc of intermediate-high densities.
However, these subpopulations are dependent on SR-BI lev-
els to a lower extent as compared with the low density HCVfrg
subpopulations. Indeed, strikingly, we demonstrate that HCV-
frg subpopulations have a non-homogeneous reliance on SR-BI
expression levels for entry. Especially, SR-BI overexpression
revealed that entry of the very low density populations (i.e.	1.05
g/ml) are the most dependent on the level of SR-BI expression
because its overexpression increased infectivity by at least
10–100-fold as compared with the HCV particles of alternative
densities (i.e. up to 10-fold). SR-BI is a natural receptor for HDL
but also for native LDL, oxidizedLDL, andVLDL (48). Becausewe
showed that SR-BI-mediated HCVfrg entry is independent of its
capacity to bind E2 and because we and others have found that
SR-BI likely interacts with HCV particles via lipoprotein compo-
nents (23, 42, 43), we can argue that in low density HCVfrg popu-
lations (i.e.	1.05 g/ml, which corresponds to the superior limit of
LDLdensity), thehighamountof serumLDLcompetedwithHCV
for SR-BI binding. Thus, increasing the SR-BI expression level
would improve binding of low density HCVfrg populations. This
assumption is congruent with a previous demonstration that the
interaction between serum-derived HCV and SR-BI was com-
peted out by VLDL (59). Alternatively, SR-BI overexpressionmay
prevent, at leastpartially, bindingofviralparticles toLDLreceptor,
which has been demonstrated to be a receptor conducive to a
“non-productive” infection (60). In contrast, in theHCVccmodel,
SR-BI expression is not differentially limiting for entry of lowden-
sity viral particles perhaps because the concentration of lipopro-
teins in the supernatant of hepatoma cell lines is lower as depicted
by lower levels of the representative components apoE and apoB
(Fig. 1C) compared with the serum of infected mice. Indeed, sta-
tistical analyses highlighted a significant increase of infectivity in
HCVfrg low density populations (i.e.	1.05 g/ml) upon SR-BI up-
regulation compared with HCVcc low density populations. The
levels of SR-BI expression in the liver are known to vary upon
various stimulations, including thequantity andnatureof intracel-
lular lipids (61) and external stimulation by dietary compounds
such as lipids or fibrates (62–64). Such variations might have a
great impact on viral entry and spread, especially for the low den-
sity virus because of its potentially high specific infectivity in vivo
and its resistance to neutralization by antibodies (50).
In conclusion, our results highlight previously uncharacterized
divergences between in vivo and in vitro produced HCV particles
with respect to their composition and biophysical properties,
which imprint their infectivity and receptor usage. Thus, human-
ized liver mouse models represent a powerful tool to investigate
the interplay between HCV and liver components and to under-
stand how the hepatic environment influences HCV biology.
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